Afabicin Oral

Phase 1

DDebiopharm International SA

Afabicin Oral is one of 15 therapeutic programs targeting Renal Impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Renal ImpairmentNot yet recruiting

Renal ImpairmentPhase 1

Not yet recruiting

Competition

Competitive Landscape

15 competitors in Renal Impairment

#DrugCompanyPhaseTrials

Zyvox

Pfizer

Approved

1 2

Fludara

Sanofi

Phase 1

1 3

Grafapex

MMedexus Pharma, Inc.

Phase 1

1 4

Nemtabrutinib

Merck & Co.

Phase 1

1 5

LY3537031

Eli Lilly

Phase 1

1 6

GZR18

GGan & Lee Pharmaceuticals.

Phase 1

1 7

D-2570

IInventisBio Co., Ltd

Phase 1

1 8

ASTX727

Taiho Oncology, Inc.

Phase 1

1 9

RO7795081

Roche

Phase 1

1 10

PKN605

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Renal Impairment

NCT07758608

Clinical

Trials by Indication[1]

Renal Impairment1 trial

An Open-Label, Adaptive Single-Dose Trial to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Afabicin

Not yet recruiting·DDebiopharm International SA·Phase 1·NCT07758608·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Afabicin Oral. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Afabicin Oral. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Debiopharm International SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: DDebiopharm International SA

Afabicin Oral

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Renal Impairment1 trial

References

Drug Info

Quick Facts

Related News